{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:30:21Z","timestamp":1793968221755,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-025-02050-5","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T13:41:14Z","timestamp":1748612474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Aromatase inhibitors therapy and major osteoporotic fracture risk in postmenopausal breast cancer patients: a nationwide real-world cohort study"],"prefix":"10.1186","volume":"27","author":[{"given":"Pin-Han","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Fang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"issue":"8","key":"2050_CR1","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1016\/S2214-109X(20)30215-1","volume":"8","author":"E Heer","year":"2020","unstructured":"Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8(8):e1027\u201337.","journal-title":"Lancet Glob Health"},{"issue":"5","key":"2050_CR2","doi-asserted-by":"publisher","first-page":"R283","DOI":"10.1530\/ERC-17-0425","volume":"25","author":"TV Augusto","year":"2018","unstructured":"Augusto TV, Correia-da-Silva G, Rodrigues CMP, Teixeira N, Amaral C. Acquired resistance to aromatase inhibitors: where we stand! Endocr Relat Cancer. 2018;25(5):R283\u2013301.","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2050_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast Cancer treatment: A review. JAMA. 2019;321(3):288\u2013300.","journal-title":"JAMA"},{"issue":"9793","key":"2050_CR4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"G Collaborative","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019, Collaborative G, Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant Tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771\u201384.","journal-title":"Lancet"},{"issue":"12","key":"2050_CR5","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00432-007-0297-7","volume":"133","author":"S Paepke","year":"2007","unstructured":"Paepke S, Jacobs VR, Ohlinger R, Warm M, Kummel S, Thomas A, et al. Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching. J Cancer Res Clin Oncol. 2007;133(12):905\u201316.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2050_CR6","doi-asserted-by":"publisher","first-page":"713700","DOI":"10.3389\/fendo.2021.713700","volume":"12","author":"T Hyder","year":"2021","unstructured":"Hyder T, Marino CC, Ahmad S, Nasrazadani A, Brufsky AM. Aromatase Inhibitor-Associated musculoskeletal syndrome: Understanding mechanisms and management. Front Endocrinol (Lausanne). 2021;12:713700.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"31","key":"2050_CR7","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1200\/JCO.19.01696","volume":"37","author":"CL Shapiro","year":"2019","unstructured":"Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol. 2019;37(31):2916\u201346.","journal-title":"J Clin Oncol"},{"key":"2050_CR8","doi-asserted-by":"publisher","first-page":"174550572211494","DOI":"10.1177\/17455057221149493","volume":"19","author":"M Malagrino","year":"2023","unstructured":"Malagrino M, Zavatta G. Review of bone health in women with Estrogen receptor-positive breast cancer receiving endocrine therapy. Womens Health (Lond). 2023;19:17455057221149493.","journal-title":"Womens Health (Lond)"},{"issue":"4","key":"2050_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1210\/er.2008-0016","volume":"30","author":"RJ Santen","year":"2009","unstructured":"Santen RJ, Brodie H, Simpson ER, Siiteri PK, Brodie A. History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev. 2009;30(4):343\u201375.","journal-title":"Endocr Rev"},{"issue":"5","key":"2050_CR10","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1016\/j.clbc.2021.04.009","volume":"21","author":"CL Shapiro","year":"2021","unstructured":"Shapiro CL. Bone-modifying agents (BMAs) in breast Cancer. Clin Breast Cancer. 2021;21(5):e618\u201330.","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"2050_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s44276-024-00059-5","volume":"2","author":"A Mirza","year":"2024","unstructured":"Mirza A, Naing ZW, Khonsari P, Khan H, Abbas AK, Nisar MK. Aromatase inhibitors and fracture prevention - do 2017 guidelines work in real world? BJC Rep. 2024;2(1):36.","journal-title":"BJC Rep"},{"issue":"9453","key":"2050_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60\u20132.","journal-title":"Lancet"},{"issue":"5","key":"2050_CR13","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","volume":"25","author":"AS Coates","year":"2007","unstructured":"Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with Tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1\u201398. J Clin Oncol. 2007;25(5):486\u201392.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2050_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","volume":"8","author":"RE Coleman","year":"2007","unstructured":"Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the intergroup exemestane study (IES): a randomised controlled study. Lancet Oncol. 2007;8(2):119\u201327.","journal-title":"Lancet Oncol"},{"issue":"17","key":"2050_CR15","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/jnci\/dji250","volume":"97","author":"PE Goss","year":"2005","unstructured":"Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following Tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262\u201371.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2050_CR16","first-page":"562","volume":"32","author":"KJ Jerzak","year":"2018","unstructured":"Jerzak KJ, Raphael J, Desautels DN, Blanchette PS, Tyono I, Pritchard KI. Bone-Targeted therapy in early breast Cancer. Oncol (Williston Park). 2018;32(11):562\u20139.","journal-title":"Oncol (Williston Park)"},{"issue":"5","key":"2050_CR17","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.jfma.2019.01.012","volume":"118","author":"CJ Chiang","year":"2019","unstructured":"Chiang CJ, Wang YW, Lee WC. Taiwan\u2019s nationwide cancer registry system of 40 years: past, present, and future. J Formos Med Assoc. 2019;118(5):856\u20138.","journal-title":"J Formos Med Assoc"},{"issue":"10","key":"2050_CR18","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/pds.4267","volume":"27","author":"WH Kao","year":"2018","unstructured":"Kao WH, Hong JH, See LC, Yu HP, Hsu JT, Chou IJ, et al. Validity of cancer diagnosis in the National health insurance database compared with the linked National Cancer registry in Taiwan. Pharmacoepidemiol Drug Saf. 2018;27(10):1060\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2050_CR19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","volume":"11","author":"CY Hsieh","year":"2019","unstructured":"Hsieh CY, Su CC, Shao SC, Sung SF, Lin SJ, Kao Yang YH, et al. Taiwan\u2019s National health insurance research database: past and future. Clin Epidemiol. 2019;11:349\u201358.","journal-title":"Clin Epidemiol"},{"issue":"4","key":"2050_CR20","first-page":"347","volume":"30","author":"MH Lin","year":"2011","unstructured":"Lin MH, Yang AC, Wen TH. Using regional differences and demographic characteristics to evaluate the principles of Estimation of the residence of the population in National health insurance research databases (NHIRD). Taiwan Gong Gong Wei Sheng Za Zhi. 2011;30(4):347.","journal-title":"Taiwan Gong Gong Wei Sheng Za Zhi"},{"issue":"1","key":"2050_CR21","first-page":"1","volume":"4","author":"CY Liu","year":"2006","unstructured":"Liu CY, Hung YT, Chuang YL, Chen YJ, Weng WS, Liu JS, et al. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manag. 2006;4(1):1\u201322.","journal-title":"J Health Manag"},{"issue":"9","key":"2050_CR22","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1007\/s00198-011-1713-z","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011;22(9):2395\u2013411.","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"2050_CR23","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1016\/j.jfma.2023.05.037","volume":"122","author":"SH Fu","year":"2023","unstructured":"Fu SH, Yu PY, Li CY, Hung CC, Lee CC, Chen HY, et al. Diagnostic accuracy of algorithms to define incident and second hip fractures: A Taiwan validation study. J Formos Med Assoc. 2023;122(Suppl 1):S82\u201391.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"2050_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11657-025-01510-x","volume":"20","author":"CF Huang","year":"2025","unstructured":"Huang CF, Lin SM, Hsu JC, Kosik RO, Chan WP. Antiresorptive injections in older adult patients with prior osteoporotic fractures: a real-world observational study. Arch Osteoporos. 2025;20(1):25.","journal-title":"Arch Osteoporos"},{"issue":"1","key":"2050_CR25","doi-asserted-by":"publisher","first-page":"27544","DOI":"10.1038\/s41598-024-79297-z","volume":"14","author":"CY Wu","year":"2024","unstructured":"Wu CY, Tsai CF, Hsu YH, Yang HY. Exploring mortality risk factors and specific causes of death within 30 days after hip fracture hospitalization. Sci Rep. 2024;14(1):27544.","journal-title":"Sci Rep"},{"issue":"5","key":"2050_CR26","doi-asserted-by":"publisher","first-page":"101465","DOI":"10.1016\/j.diabet.2023.101465","volume":"49","author":"ZY Peng","year":"2023","unstructured":"Peng ZY, Wang YT, Chang CS, Wu CH, Ou HT. Effect of SGLT2 inhibitors versus DPP4 inhibitors on major and non-major osteoporotic fracture risks among general and high-risk type 2 diabetes patients: A nationwide retrospective cohort study. Diabetes Metab. 2023;49(5):101465.","journal-title":"Diabetes Metab"},{"issue":"4","key":"2050_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-Value. Ann Intern Med. 2017;167(4):268\u201374.","journal-title":"Ann Intern Med"},{"key":"2050_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","volume":"7","author":"P Hadji","year":"2017","unstructured":"Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, et al. Management of aromatase Inhibitor-Associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol. 2017;7:1\u201312.","journal-title":"J Bone Oncol"},{"issue":"2","key":"2050_CR29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/jbmr.3886","volume":"35","author":"M Pineda-Moncusi","year":"2020","unstructured":"Pineda-Moncusi M, Garcia-Giralt N, Diez-Perez A, Servitja S, Tusquets I, Prieto-Alhambra D, et al. Increased fracture risk in women treated with aromatase inhibitors versus Tamoxifen: beneficial effect of bisphosphonates. J Bone Min Res. 2020;35(2):291\u20137.","journal-title":"J Bone Min Res"},{"key":"2050_CR30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.breast.2021.09.010","volume":"60","author":"PS Blanchette","year":"2021","unstructured":"Blanchette PS, Lam M, Le B, Richard L, Shariff SZ, Ouedraogo AM, et al. The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. Breast. 2021;60:295\u2013301.","journal-title":"Breast"},{"issue":"2","key":"2050_CR31","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s11764-017-0666-4","volume":"12","author":"JM Neuner","year":"2018","unstructured":"Neuner JM, Shi Y, Kong AL, Kamaraju S, Smith EC, Smallwood AJ, et al. Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy. J Cancer Surviv. 2018;12(2):268\u201375.","journal-title":"J Cancer Surviv"},{"issue":"8","key":"2050_CR32","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/jbmr.3726","volume":"34","author":"WD Leslie","year":"2019","unstructured":"Leslie WD, Morin SN, Lix LM, Niraula S, McCloskey EV, Johansson H, et al. Performance of FRAX in women with breast Cancer initiating aromatase inhibitor therapy: A Registry-Based cohort study. J Bone Min Res. 2019;34(8):1428\u201335.","journal-title":"J Bone Min Res"},{"issue":"4","key":"2050_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/1759720X18759291","volume":"10","author":"OL Tseng","year":"2018","unstructured":"Tseng OL, Spinelli JJ, Gotay CC, Ho WY, McBride ML, Dawes MG. Aromatase inhibitors are associated with a higher fracture risk than Tamoxifen: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis. 2018;10(4):71\u201390.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"2050_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10549-015-3661-3","volume":"155","author":"N Schmidt","year":"2016","unstructured":"Schmidt N, Jacob L, Coleman R, Kostev K, Hadji P. The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the united Kingdom. Breast Cancer Res Treat. 2016;155(1):151\u20137.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"2050_CR35","doi-asserted-by":"publisher","first-page":"e0130725","DOI":"10.1371\/journal.pone.0130725","volume":"10","author":"CH Chang","year":"2015","unstructured":"Chang CH, Chen SJ, Liu CY. Fracture risk and adjuvant therapies in young breast cancer patients: a population-based study. PLoS ONE. 2015;10(6):e0130725.","journal-title":"PLoS ONE"},{"issue":"8","key":"2050_CR36","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1001\/jama.2010.1205","volume":"304","author":"BM Psaty","year":"2010","unstructured":"Psaty BM, Siscovick DS. Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction. JAMA. 2010;304(8):897\u20138.","journal-title":"JAMA"},{"key":"2050_CR37","unstructured":"Network NCC. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Version 6.2020. 2020."},{"key":"2050_CR38","doi-asserted-by":"publisher","first-page":"829875","DOI":"10.3389\/fonc.2021.829875","volume":"11","author":"A de Sire","year":"2021","unstructured":"de Sire A, Lippi L, Venetis K, Morganti S, Sajjadi E, Curci C, et al. Efficacy of antiresorptive drugs on bone mineral density in Post-Menopausal women with early breast Cancer receiving adjuvant aromatase inhibitors: A systematic review of randomized controlled trials. Front Oncol. 2021;11:829875.","journal-title":"Front Oncol"},{"issue":"1","key":"2050_CR39","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11764-021-00993-0","volume":"17","author":"ML Kwan","year":"2023","unstructured":"Kwan ML, Lo JC, Laurent CA, Roh JM, Tang L, Ambrosone CB, et al. A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting. J Cancer Surviv. 2023;17(1):139\u201349.","journal-title":"J Cancer Surviv"},{"key":"2050_CR40","doi-asserted-by":"publisher","first-page":"100409","DOI":"10.1016\/j.jbo.2021.100409","volume":"32","author":"N Hong","year":"2022","unstructured":"Hong N, Burm SW, Treece G, Ye Kim J, Hwan Kim M, Lee S, et al. Protective effect of bisphosphonate on the cortical bone at key locations of the femur in aromatase inhibitor-associated bone loss: A three-dimensional cortical bone mapping study. J Bone Oncol. 2022;32:100409.","journal-title":"J Bone Oncol"},{"issue":"4","key":"2050_CR41","first-page":"505","volume":"65","author":"FAP Nunes","year":"2021","unstructured":"Nunes FAP, de Farias MLF, Oliveira FP, Vieira LN, Lima LFC, de Paula Paranhos FN, et al. Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density. Arch Endocrinol Metab. 2021;65(4):505\u201311.","journal-title":"Arch Endocrinol Metab"},{"issue":"6","key":"2050_CR42","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00774-021-01239-w","volume":"39","author":"S Kuba","year":"2021","unstructured":"Kuba S, Watanabe K, Chiba K, Matsumoto M, Yamanouchi K, Fukushima A, et al. Adjuvant endocrine therapy effects on bone mineral density and microstructure in women with breast cancer. J Bone Min Metab. 2021;39(6):1031\u201340.","journal-title":"J Bone Min Metab"},{"key":"2050_CR43","doi-asserted-by":"publisher","first-page":"100292","DOI":"10.1016\/j.jbo.2020.100292","volume":"22","author":"U Stumpf","year":"2020","unstructured":"Stumpf U, Kostev K, Siebenburger G, Bocker W, Hadji P. Influence of chemotherapy and endocrine treatment on fractures in postmenopausal women with breast cancer - a retrospective cohort study. J Bone Oncol. 2020;22:100292.","journal-title":"J Bone Oncol"},{"issue":"1","key":"2050_CR44","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","volume":"69","author":"P Hadji","year":"2009","unstructured":"Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol. 2009;69(1):73\u201382.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2050_CR45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/GME.0000000000000515","volume":"23","author":"P Villa","year":"2016","unstructured":"Villa P, Lassandro AP, Amar ID, Vacca L, Moruzzi MC, Ferrandina G, et al. Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer. Menopause. 2016;23(1):33\u20139.","journal-title":"Menopause"},{"issue":"9","key":"2050_CR46","doi-asserted-by":"publisher","first-page":"e1911080","DOI":"10.1001\/jamanetworkopen.2019.11080","volume":"2","author":"R Pedersini","year":"2019","unstructured":"Pedersini R, Amoroso V, Maffezzoni F, Gallo F, Turla A, Monteverdi S, et al. Association of fat body mass with vertebral fractures in postmenopausal women with early breast Cancer undergoing adjuvant aromatase inhibitor therapy. JAMA Netw Open. 2019;2(9):e1911080.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2050_CR47","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1158\/1078-0432.CCR-10-1595","volume":"17","author":"BJ Edwards","year":"2011","unstructured":"Edwards BJ, Raisch DW, Shankaran V, McKoy JM, Gradishar W, Bunta AD, et al. Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clin Cancer Res. 2011;17(3):560\u20138.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2050_CR48","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00223-015-0046-x","volume":"97","author":"SJ Lee","year":"2015","unstructured":"Lee SJ, Kim KM, Brown JK, Brett A, Roh YH, Kang DR, et al. Negative impact of aromatase inhibitors on proximal femoral bone mass and geometry in postmenopausal women with breast Cancer. Calcif Tissue Int. 2015;97(6):551\u20139.","journal-title":"Calcif Tissue Int"},{"issue":"1\u20135","key":"2050_CR49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jsbmb.2005.04.015","volume":"95","author":"J Geisler","year":"2005","unstructured":"Geisler J, Lonning PE. Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations. J Steroid Biochem Mol Biol. 2005;95(1\u20135):75\u201381.","journal-title":"J Steroid Biochem Mol Biol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02050-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-02050-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02050-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T15:07:37Z","timestamp":1748617657000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-025-02050-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2050"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-02050-5","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study (CYCH-IRB No 2023053) was approved by the Institutional Review Board of the Ditmanson Medical Foundation Chia-Yi Christian Hospital, Taiwan. Since the data were anonymized, informed consent was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}